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Abstract Prion diseases are transmissible neurodegener-
ative disorders of mammalian species and include scrapie,
bovine spongiform encephalopathy (BSE), and variant
Creutzfeldt-Jakob disease (vCJD). The prion protein (PrP)
plays a key role in the disease, with coding polymorphism
in both human and mouse inﬂuencing disease susceptibility
and incubation time, respectively. Other genes are also
thought to be important and a plausible candidate is Sprn,
which encodes the PrP-like protein Shadoo (Sho). Sho is
expressed in the adult central nervous system and exhibits
neuroprotective activity reminiscent of PrP in an in vitro
assay. To investigate the role of Sprn in prion disease
incubation time we sequenced the open reading frame
(ORF) in a diverse panel of mice and saw little variation
except in strains derived from wild-trapped mice.
Sequencing the untranslated regions revealed polymor-
phisms that allowed us to carry out an association study of
incubation period in the Northport heterogeneous stock of
mice inoculated with Chandler/RML prions. We also
examined the expression level of Sprn mRNA in the brains
of normal and prion-infected mice and saw no correlation
with either genotype or incubation time. We therefore
conclude that Sprn does not play a major role in prion
disease incubation time in these strains of mice.
Introduction
Prion diseases or transmissible spongiform encephalopa-
thies are fatal neurodegenerative disorders and include
scrapie in sheep, bovine spongiform encephalopathy (BSE)
in cattle, and variant Creutzfeldt-Jakob disease (vCJD) in
humans. They exhibit a long, clinically silent incubation
period and share similar neuropathological signs such as
vacuolation, gliosis, neuronal loss, and the accumulation of
abnormal forms of the prion protein (PrP
Sc).
The prion protein (PrP) plays a central role in prion dis-
ease yet its normal function remains elusive. Mice lacking
PrP are grossly normal with only subtle abnormalities but
are completely resistant to prion infection, thus conﬁrming
the central importance of PrP in prion propagation and dis-
ease (Bueler et al. 1992, 1993). Mutations in the human
prion gene (PRNP) are linked to over 30 inherited forms of
human prion disease (Collinge 2001;Mead 2006).Variation
in human PrP (M129V) is associated with susceptibility to
prion disease (Collingeetal. 1991;Mead etal.2003;Palmer
et al. 1991), and polymorphisms in the mouse prion gene,
Prnp
a (Leu-108, Thr-189) and Prnp
b (Phe-108, Val-189),
are associated with short and long incubation times,
respectively(Mooreetal.1998;Westawayetal.1987).Prnp
is the main genetic determinant of prion disease incubation
timeinmice;however,severalquantitativetraitlocus(QTL)
mapping studies have demonstratedthatothergenes are also
important (Lloyd et al. 2001, 2002; Manolakou et al. 2001;
Moreno et al. 2003; Stephenson et al. 2000). While these
studies have been very successful, the genomic regions
identiﬁed were large and the quantitative trait genes them-
selves are yet to be identiﬁed.
Two paralogs of PrP that share the structural charac-
teristics of PrP have been identiﬁed. The Doppel protein
(Dpl) is encoded by the Prnd gene and maps adjacent to
Prnp on Mmu2. Dpl is normally expressed in testis and
plays an important role in spermatogenesis and is unlikely
to be relevant in prion disease pathogenesis (Behrens
et al. 2002). However, aberrant expression of Dpl in the
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0/0 mice results in a neurodegenerative
phenotype that is rescued by the presence of PrP (Moore
et al. 2001; Nishida et al. 1999; Rossi et al. 2001). This is
very similar to the results obtained with transgenic mice
expressing N-terminal deletion mutants of PrP (DPrP)
(Shmerling et al. 1998). These studies suggested a model
that proposes that PrP initiates a cell survival signal
through interaction with a ligand (LPrP) that is also able to
bind Dpl and DPrP, albeit with lower afﬁnity. This also led
to the suggestion that a PrP-like molecule named p could
substitute for PrP in the knockout mice, thus explaining
their developmentally normal phenotype.
Based on comparative gene analysis, a new PrP-like
molecule named Shadoo (Sho, shadow of prion protein) has
been identiﬁed (Premzl et al. 2003). Sho is encoded by the
Sprn gene and maps to Mmu7 (HSA10). Like Prnp,i ti s
predicted to have a glycophosphotidylinositol (GPI) anchor
and a conserved hydrophobic region. It has been demon-
strated that PrP and Sho have an overlapping, although not
identical,patternofexpressioninthecentralnervoussystem,
and like PrP, Sho was able to rescue the neurotoxic pheno-
type of both Dpl and DPrP, suggesting that Sho could be a
candidate for p (Watts et al. 2007). It was also demonstrated
that prion-infected mice have a signiﬁcant reduction in Sho.
Sho has been further implicated in prion disease by the
demonstration that a frameshift mutation at codon 46 was
found in two vCJD patients but not in controls, and an
additional coding polymorphism (T7M) was associated
with sporadic CJD (Beck et al. 2008).
Three QTL studies have identiﬁed loci on Mmu7 as
being linked to prion disease incubation time with sug-
gestive levels of linkage (Lloyd et al. 2001; Moreno et al.
2003; Stephenson et al. 2000). These studies used different
mouse and prion strains and the loci were not overlapping.
The study of Stephenson et al. (2000) showed a peak of
linkage (LOD = 2.2) at marker D7Mit259 which maps
within 5 Mb of Sprn.
Taking all these data together, we considered that Sprn
was a good candidate gene for prion disease incubation
time in mice. In this study we sequenced Sprn to identify
polymorphisms and used a heterogeneous stock (HS) of
mice to look for an association of Sprn with incubation
time. We further examined the level of mRNA expression
in the HS parental strains and compared expression in both
normal and prion-infected mice.
Materials and methods
Mice
DNA was obtained from The Jackson Laboratory (Bar
Harbor, ME, USA) or as a gift from Jean-Louis Gue ´net
(Institute Pasteur, Paris). Live MAI/Pas and PWK/Pas mice
were obtained from Jean-Louis Gue ´net; JU/FaCt (gift of
Bruce Cattanach) and CAST/Ei were obtained from the
Medical Research Council Mammalian Genetics Unit
(Harwell, UK). CD-1 mice were obtained from Charles
River and all other inbred lines of mice were obtained from
Harlan UK Ltd. The Northport Heterogeneous Stock (HS)
(gift of R. Hitzemann, Portland, OR, USA) was received as
28 breeding pairs; offspring from these were randomly
mated to produce a total of 49 pairs. One thousand ﬁfty-two
offspring (generation 37) were used for inoculation. Mice
were identiﬁed by individual transponder tags (Trovan) and
0.5-cm tail biopsies were obtained for DNA extraction.
Inoculation and phenotyping
Mice were anaesthetized with isoﬂuorane/O2 and inocu-
lated intracerebrally into the right parietal lobe with 30 ll
Chandler/RML prions as previously described (Lloyd et al.
2001). Incubation time was calculated retrospectively after
a deﬁnite diagnosis of scrapie had been made; it was
deﬁned as the number of days from inoculation to the onset
of clinical signs (Carlson et al. 1986). This was assessed by
daily examination for neurological signs of disease. Ani-
mals were culled as soon as clinical scrapie was conﬁrmed
or if they showed signs of distress. All procedures were
conducted in accordance with UK regulations (Local Eth-
ics approval and Home Ofﬁce regulation) and international
standards on animal welfare.
Statistical analysis
Incubation time data were collected for 1052 Northport HS
mice. The range in incubation time was 103-229 days
(mean ± SD = 145 ± 15 days). The normality of the
incubation time distribution was established using the
Anderson-Darling normality test (P = 1). To look for an
association between incubation time and genotype, an
ANOVA was used with pairwise comparisons carried out
using Fisher’s protected least signiﬁcant difference (PLSD)
test (Statview, SAS Institute Inc., Cary, NC, USA).
PCR and sequencing
DNA was extracted from 0.5-cm tail biopsies using a DNA
extraction kit (Promega, Madison, WI, USA) and resus-
pended in 50 ll TE (10 mM Tris-HCl, 1 mM EDTA, pH
7.5). A 1:10 dilution of this stock was used as template for
subsequent PCRs. Oligonucleotides were synthesized by
Sigma-Genosys (Sigma-Aldrich, St. Louis, MO, USA).
PCR reactions for subsequent sequencing were all carried
out in 25 ll on 96-well plates using MegaMix Blue
(Microzone Ltd, West Sussex, UK) according to the
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PCR conditions were determined empirically but, in gen-
eral, cycling conditions using a PTC-225 thermal cycler
(MJ Research, Waltham, MA, USA) were as follows: 94C
for 10 min; 94C for 30 sec, 60C for 45 sec, 72C for
60 sec for 40 cycles; 72C for 5 min. PCR products were
cleaned using Microclean (Microzone Ltd) according to the
manufacturer’s instructions and resuspended in H2O. PCR
product (100-200 ng) was added to a 15-ll sequencing
reaction that included 5 pmol of either the forward or the
reverse primer, 1 ll BigDye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA,
USA), and 5 ll Better Buffer (Microzone Ltd). Cycling
conditions were 95C for 30 sec, 50C for 15 sec, 60C for
120 sec for 30 cycles. Reactions were ethanol precipitated,
washed in 70% ethanol, and resuspended in 10 ll
MegaBACE loading solution (GE Healthcare BioSciences,
Piscataway, NJ, USA). Products were detected on a
MegaBACE1000 capillary sequencer (GE Healthcare).
Samples were injected at 3 kV for 40 sec and run at 9 kV
for 100 min.
Allele discrimination
Primers and probes for Sprn genotyping were designed
using criteria deﬁned by Applied Biosystems and Primer-
Express software (Applied Biosystems). MGB probes
labeled with either Vic or Fam were purchased from
Applied Biosystems and primers for ampliﬁcation were
obtained from Sigma-Genosys. Oligonucleotide sequen-
ces were as follows: F-50-GCCGCACCTTTCCGCT-30;
R-50-CCTCCCCTACTTACTGGTCACAAG-30; G-speciﬁc
probe 50-Vic-TAGGGGCCGTGACC-MGB-30; T-speciﬁc
probe 50-Fam-TAGGGGCCTTGACC-MGB-30. One pico-
mole of each probe and 2.5 pmol of each primer were used
in a 5-ll reaction on a 7500 Fast Real-time PCR System
(Applied Biosystems) using RoxMegaMix Gold (Microz-
one Ltd). Cycling conditions were 95C for 5 min; 95C
for 15 sec and 60C for 60 sec for 40 cycles.
RNA extraction and quantitative RT-PCR
RNA was extracted from whole brains from either unin-
fected or RML terminally sick mice. Six- to eight-week-old
adult male mice were used for all normal brains. Tissue was
homogenized using a Ribolyser according to the manufac-
turer’s instructions (Hybaid Ltd, Ashford, UK). RNA was
prepared using either a RNeasy Maxi kit (Qiagen, Valencia,
CA, USA) or a TRIreagent kit (Ambion, Austin, TX, USA)
according to the manufacturer’s instructions. Samples were
treated with DNaseI (Qiagen) and puriﬁed further using
RNeasy Mini columns (Qiagen) according to the manu-
facturer’s instructions. Four micrograms of total RNA was
reverse transcribed with AMV reverse transcriptase and
random primers from the Reverse Transcription System
(Promega) according to the manufacturer’s instructions.
Reactions with no reverse transcription were also carried
out for each sample to ensure no genomic DNA contami-
nation. Sprn real-time PCR was carried out on a 7500 Fast
Real-time PCR System (Applied Biosystems) in a total
volume of 15 ll using 1 ll cDNA (200-300 ng) and Rox-
MegaMix Gold (Microzone Ltd) according to the manu-
facturer’s instructions. Primers (6 pmol) SPRNF-50-TGG
GCCCGTCTGATTCTG-30 and SPRNR-50-TCAACTA-
TAAGTCCCTCTGGTTCCA-30 and probe (3 pmol) 50-Fa
m-ACTAAAGCCCCCAAAGACCTTGAGCCTC-Tamra-
30 were designed using PrimerExpress software (Applied
Biosystems) and supplied by Sigma-Genosys. Endogenous
controls (GAPDH and b-actin) were VIC-labeled and sup-
plied as a kit by Applied Biosystems. Primers Thy-F-50-CA
GGCACCCTTGGGATACC-30 and Thy-R-50-TGGAACT
ATATCCCGACCAACCT-30and probe 50-Vic-ACGTAC
CGCTCCCGCGTCACC-Tamra-30 (Applied Biosystems)
for an additional endogenous control, Thy-1, were designed
and used as above. Endogenous controls were duplexed
with the Sprn reaction according to the manufacturer’s
instructions or for Thy-1 using the same primer and probe
concentrations as for Sprn. All reactions were carried out in
triplicate using the following cycling conditions: 95C for
5 min; 95C for 15 s and 60C for 60 sec for 40 cycles.
Each sample was quantiﬁed using all three endogenous
controls. The geometric mean of these data was used for
statistical analyses and display in Fig. 1.
Results
Sprn sequencing
To investigate whether coding changes in the mouse Sho
protein are likely to inﬂuence prion disease incubation
time, we sequenced the open reading frame (ORF) of Sprn.
The 441-bp (147 amino acids) ORF of Sprn is encoded
entirely within exon 2 and is characterised by an N-ter-
minal region containing tetrarepeats rich in arginine and
glycine residues, a hydrophobic domain, and an N-glyco-
sylation site (Premzl et al. 2003). We sequenced one mouse
DNA sample from each of 24 lines of mice chosen to
reﬂect the three alleles of Prnp (Table 1). The most com-
monly used inbred lines are all Prnp
a; however, Prnp
b is
seen in JU/FaCt and VM/Dk mice, while Prnp
c has been
recorded only in MAI/Pas mice (Carlson et al. 1988; Lloyd
et al. 2004). The Prnp
a inbred lines have been demon-
strated by us and others to show variation in prion disease
incubation time and have been widely used in prion
research (Lloyd and Collinge 2005). We also chose lines
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(PWK/Pas, MBT/Pas, and MAI/Pas), M. m. domesticus
(WLA/Pas and WMP/PAs), M. spretus (SEG/Pas), and M.
m. castaneus (CAST/Ei), to capture as much sequence
diversity as possible.
Across all 24 strains we detected ﬁve polymorphisms in
the ORF, only two of which were coding changes (Table 1).
Each coding change was seen only in a single line, with
G95V and L134F present in CAST/Ei and SEG/Pas,
respectively. SEG/Pas was also the only strain for which we
detected noncoding polymorphisms at codons 11 (CTG ?
CTA) and 136 (GGC ? GGT). An additional synonymous
polymorphism occurred at codon 108 (GGA ? GGG),
which was seen in four of the wild-trapped mice (MAI/Pas,
PWK/Pas, CAST/Ei, and SEG/Pas). No variation was seen
acrosstheORFoftheotherclassicalinbredstrains.Thisisof
particular interest as this group contains two Prnp
b allele
mice. There is considerable variation in incubation time
between the inbred Prnp
a mice, ranging from 108 ± 1 days
(NZW) to 143 ± 1 days (C57BL/6) (Kingsbury et al. 1983;
LloydandCollinge2005;Westawayetal.1987)eventhough
there are no coding polymorphisms in the Sho ORF. This
suggeststhatatleastinthesestrains,variationsintheprimary
sequence of Sho are unlikely to be associated with prion
disease incubation time.
The mouse Sprn gene contains a short 50 UTR (126 bp)
spanning exons 1 and 2 and a long 30 UTR (2586 bp)
encoded by exon 2. The promoter and other regulatory
regions have yet to be deﬁned. As it is possible that reg-
ulatory regions within the UTRs may inﬂuence prion dis-
ease incubation time, we extended our sequencing to cover
these regions although only in a subset of inbred lines (A/J,
AKR/J, BALB/cJ, C3H/HeJ, C57BL/6 J, CBA/J, DBA/2 J,
LP/J) that are the parental strains for the Northport Het-
erogeneous Stock (HS) (Hitzemann et al. 1994).
Two polymorphisms were seen in the 50 UTR and one in
the 30 UTR. In addition, four SNPs were seen in the intron
1 sequence ﬂanking the 50 UTR (Table 2). Only one strain
distribution pattern (SDP) was seen with Group I (A, AKR,
BALB, C3H, C57BL6, DBA, and LP) having one allele
and Group II (CBA) possessing the other variant. These
polymorphisms do not occur within any known splicing
Fig. 1 Sprn mRNA expression. cDNA was prepared from the whole
brains of uninfected 6-8-week-old male mice or mice at the terminal
stages of disease following intracerebral inoculation with Chandler/
RML mouse-adapted scrapie prions. All samples were duplexed for
Sprn (Fam-label) and an endogenous control, GAPDH, b-actin,o r
Thy-1 (Vic-label). Samples were run in triplicate with n = 6 for each
mouse strain/group (except CBA where n = 3 and NZW-RML where
n = 5). Mean ± SEM. Sprn mRNA expression level is expressed in
arbitrary units as normalised by the geometric mean of the quantity of
the endogenous controls (y axis). a Individual parental strains of the
HS mice. b Mouse strains are grouped according to the strain
distribution pattern seen in Sprn (Group I = A, AKR, BALB, C3H,
C57, DBA; Group II = CBA). c Comparison of Sprn mRNA
expression in normal and RML infected mice. Dark grey and light
grey bars represent uninfected and RML infected mice, respectively
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ﬁcult to predict whether they are likely to be functional.
Sprn genotyping of HS mice
Because the observed SDP is conserved across the gene,
we chose one of the 50 UTR SNPs (50 UTR #1 in Table 2)
to look for an association with prion disease incubation
time in the Northport HS. One thousand ﬁfty-two HS mice
at generation 37 were inoculated intracerebrally with
mouse-adapted scrapie prions (Chandler/RML) and incu-
bation times (in days) were determined as previously
described (Carlson et al. 1986; Lloyd et al. 2001). It is
recognised that individuals from the ends of a distribution
are more likely to share genotypes affecting the phenotype;
therefore, selective genotyping from these ends has com-
parable power to genotyping all individuals (Darvasi and
Soller 1992; Lander and Botstein 1989). Therefore,
approximately 20% of animals from each extreme of the
incubation time distribution were genotyped. The SNP was
genotyped by allelic discrimination using a 7500 Real-
Time PCR instrument (Applied Biosystems). Genotypes
were collected for 348 animals where the genotypes CC
(n = 340) and CA (n = 8) had mean incubation times of
144.1 ± 1.2 and 158.9 ± 8.4 days, respectively. Although
this suggests that an increase in incubation time may be
associated with the presence of the A allele, this is not
statistically signiﬁcant (ANOVA, P = 0.064).
Table 1 Sprn open reading
frame polymorphisms
All strains are Prnp
a unless
otherwise indicated (Carlson
et al. 1988; Lloyd et al. 2004)
L11L
CTG ? CTA
G95V
GGC ? GTC
G108G
GGA ? GGG
L134F
CTT ? TTT
G136G
GGC ? GGT
A/J G G A C C
AKR/J G G A C C
BALB/cJ G G A C C
C3H/HeJ G G A C C
C57BL6/J G G A C C
CBA/J G G A C C
DBA/2J G G A C C
LP/J G G A C C
129/Sv G G A C C
FVB/NHsd G G A C C
SWR/OlaHsd G G A C C
NZW/OlaHsd G G A C C
RIIIS/J G G A C C
SJL/OlaHsd G G A C C
JU/FaCt (Prnp
b)G G A C C
VM/Dk (Prnp
b)G G A C C
MAI/Pas(Prnp
c)G G G CC
WLA/Pas G G A C C
PWK/Pas G G G CC
WMP/Pas G G A C C
MBT/Pas G G A C C
CD-1 G G A C C
CAST/Ei G TGCC
SEG/Pas A G GT T
Table 2 HS parental strains Sprn polymorphisms
Position
(bp)
A AKR BALB C3H C57 CBA DBA LP
50 UTR
#1
73 C C C C C A C C
50 UTR
#2
89 C C C C C del C C
Intron 1 111 A A A A A G A A
Intron 1 143 C C C C C A C C
Intron 1 149 G G G G G C G G
Intron 1 155 G G G G G A G G
30 UTR 2024 G G G G G G G G
SNP positions for the transcript are numbered from the start of the 50
UTR and the intronic SNPs are shown from the start of intron 1
(genomic sequence from the UCSC genome browser, release July
2007)
del single base deletion, UTR untranslated region
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Transgenic and knockout mouse models have demonstrated
that PrP expression levels correlate directly with prion
disease incubation time (Bu ¨eler et al. 1994; Carlson et al.
1994; Collinge et al. 1995; Prusiner et al. 1990). Although
we did not detect any polymorphisms that are predicted to
affect Sprn expression, our sequencing was not exhaustive,
and particularly since the promoter and other regulatory
regions have not been deﬁned, it is possible that we have
not identiﬁed the key sites. Therefore, we compared the
Sprn mRNA expression level in the parental lines of the HS
mice. RNA was extracted from whole brains of 8-week-old
males from the parental strains of the HS (except LP).
Samples were analysed by real-time RT-PCR and norma-
lised using the geometric mean of the quantity obtained
from three endogenous controls (GAPDH, b-actin, and
Thy-1). Expression levels for individual strains are shown
in Fig. 1a. Although there are differences between the
individual strains (ANOVA, P = 0.0007), these differ-
ences do not correlate with the known Sprn genotype. This
is shown in Fig. 1b where the strains are grouped according
to the Sprn SDP (Group I = A, AKR, BALB, C3H, C57,
DBA, LP; Group II = CBA). However, if grouped by
expression levels, the inbred lines fall broadly into two
groups (Group A = A, AKR, BALB, CBA, DBA; Group
B = C3H, C57) that are signiﬁcantly different
(P = 6.5 9 10
-5). If a cis-acting factor were responsible
for this, we would expect to see the above grouping
reﬂected in a SDP; however, this has not been observed in
our sequencing. Partial low-coverage genome sequence is
available for the strains A/J, AKR/J, BALB/cByJ, C3H/
HeJ, C57BL/6 J, and DBA/2J (http://www.informatics.jax.
org/); therefore, we searched for SNPs 100 kb upstream
and downstream of Sprn that might correspond to this SDP
and did not ﬁnd any. The strain differences in expression
may therefore be explained by a trans-acting factor. We
also compared Sprn mRNA expression levels with pub-
lished incubation times; however, no correlation was
observed (R
2 = 0.21) (Carlson et al. 1994; Kingsbury et al.
1983; Westaway et al. 1987).
It has also been shown that Sho levels are dramatically
reduced in prion disease in both C3H 9 C57 F1 and
C57BL6 mice infected with RML prions (Watts et al.
2007). We therefore compared the level of Sprn mRNA
expression in the brains of uninfected and terminally sick
RML-prion-infected mice from four inbred strains
(C57BL/6OlaHsd, SJL/OlaHsd, NZW/OlaHsd, and RIIIS/
J) (Fig. 1c). In contrast to the results obtained by Watts
et al. who looked at the Sho protein, the mRNA level was
increased in RML infection in three strains (C57BL6,
P = 0.0001; NZW, P = 0.006; RIIIS, P = 0.013) and
showed no signiﬁcant difference in the remaining strain
(SJL, P = 0.1). We also compared the incubation times
(Lloyd et al. 2004) with Sprn expression levels in the
RML-infected brains and found that no correlation was
observed (R
2 = 0.26).
Discussion
Our sequencing of the Sho ORF did not identify polymor-
phisms in the commonly used inbred strains. All variants
were found in the strains derived from wild-trapped mice,
particularlyCAST/EiandSEG/Pas,whichareexpectedtobe
more diverse because they belong to the subspecies M. m.
castaneus and M. spretus, respectively. It is unclear whether
thesechangeswouldbefunctionallysigniﬁcantastheamino
acid changes do not occur within domains known to be
functionally important (Premzl et al. 2003; Watts et al.
2007). Our data suggest that unlike PrP, there is no associ-
ation of Sho amino acid polymorphisms and prion disease
incubation time in mice. This also contrasts with the asso-
ciation of two SPRN frameshift mutations in vCJD and the
T7 M polymorphisms with sporadic CJD (Beck et al. 2008).
Although there are no signiﬁcant coding changes in Sho,
it is possible that it exerts its effect on prion disease
through variation in expression level either at the level of
the mRNA or the protein. The regulation of Sprn is not
well characterised; therefore, we were able to look only at
the UTRs. We did not sequence our entire mouse panel but
focused on the inbred strains that are the parental strains of
the Northport HS so that we could use any polymorphism
found for an association study. The UTRs were well con-
served between the strains, with the only variants seen in
the CBA/J strain. Because our sequencing was not
exhaustive, it is possible that we did not see the functional
SNPs and that these represent a different SDP. We geno-
typed only one marker in the HS mice; however, this
represents the only SDP found in the UTRs. No signiﬁcant
association with prion disease incubation time was seen
with this SNP although the mean incubation time was
14.8 days longer. This may be due to underrepresentation
of the minor allele (A) in the HS. Although we cannot rule
out an association of this haplotype with prion disease
incubation time in other mouse strains and crosses, we ﬁnd
no genetic evidence of a role for Sprn in our HS mice.
Previous work has shown that Sho levels are reduced by
the clinical stage of RML prion infection (Watts et al.
2007). Our data do not replicate this ﬁnding. It is possible
that this is a reﬂection of the mouse strains used; however,
C57BL/6 was used in both studies, although it should be
noted that while we used C57BL/6JOlaHsd (supplied by
Harlan, UK), the substrain designation was not speciﬁed by
Watts et al. An alternative explanation may be that the
previous study looked at the protein level while we
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available to us; therefore, we considered that measuring the
mRNA was a reasonable substitute, particularly as we were
interested mainly in measuring cis effects on transcrip-
tional regulation. However, this may not hold true in this
case as post-transcriptional mechanisms may inhibit
translation or the protein itself may be targeted for
degradation.
In conclusion, although Sho is an evolutionary member
of the prion protein family, is reported to exhibit PrP-like
neuroprotective activity, and is a candidate for the hypo-
thetical p protein, our data do not support a major role for
Sprn in inﬂuencing the natural variation in prion disease
incubation time in these strains of mice.
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